JNJ-63576253

• CAT Number: I045578
• CAS Number: 2110428-64-1
• Molecular Formula: C23H22ClF3N6O2S
• Molecular Weight: 538.97
• Purity: ≥95%
• Synonyms: 5-[8-oxo-5-(6-piperidin-4-yloxypyridin-3-yl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile;hydrochloride
• InChI: InChI=1S/C23H21F3N6O2S.ClH/c24-23(25,26)17-10-15(13-29-18(17)11-27)31-20(33)22(6-1-7-22)32(21(31)35)14-2-3-19(30-12-14)34-16-4-8-28-9-5-16;/h2-3,10,12-13,16,28H,1,4-9H2;1H
• InChIKey: QDINJYHLAKIZLE-UHFFFAOYSA-N
• SMILES: C1CC2(C1)C(=O)N(C(=S)N2C3=CN=C(C=C3)OC4CCNCC4)C5=CC(=C(N=C5)C#N)C(F)(F)F.Cl

JNJ-63576253 (Cat No.: I045578) is a potent, selective antagonist of the orexin-1 receptor (OX1R), a G-protein–coupled receptor involved in regulating arousal, reward pathways, and stress responses. By blocking OX1R signaling, JNJ-63576253 modulates neuronal circuits linked to anxiety, addiction, and sleep–wake regulation. It has been explored as a therapeutic candidate for treating substance use disorders and related neuropsychiatric conditions. As a research tool, JNJ-63576253 enables detailed investigation of orexin biology, OX1R-selective signaling, and the therapeutic potential of targeting orexin pathways in brain disorders.

Reference

[1]. Zhang Z, et, al. Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC). J Med Chem. 2021 Jan 28;64(2):909-924.
[Content Brief]